

# Clostridium Difficile Infection and Biliary Obstruction

Marilena Stoian <sup>1,2\*</sup>

<sup>1</sup>University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania.

<sup>2</sup>Dr. Ion Cantacuzino” Clinical Hospital, Bucharest, Romania.

\*Corresponding author: Marilena Stoian, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania.

Received date: **May 04, 2021**; Accepted date: **May 17, 2021**; Published date: **May 31, 2021**

Citation: Marilena Stoian (2021). Clostridium Difficile Infection and Biliary Obstruction. *J Clinical Research and Reports*, 8(1); DOI:10.31579/2690-1919/166

Copyright: © 2021 Marilena Stoian, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Abstract

We present a case of a 38-year-old man was admitted to the hospital with biliary obstruction and *Clostridium Difficile* infection. He presented with moderate increases in the aminotransferase and bilirubin levels suggesting the diagnosis of an autoimmune hepatobiliary disease; intestinal protein loss needs to evaluate an associated inflammatory bowel disease. The clinical diagnosis of autoimmune hepatobiliary disease associated with inflammatory bowel disease is based on the patients symptoms and the presence of a protein-losing enteropathy which are more suggestive of Crohn disease, while moderate increases in the aminotransferase levels in proportion to the increase in the bilirubin level suggesting the diagnosis of primary sclerosing cholangitis. The pathological and positive diagnosis needs an endoscopic retrograde cholangiopancreatography and a biopsy of gastric and duodenum mucosae who showed severe inflammation findings that are diagnostic of Crohn disease.

**Key words:** crohn disease; endoscopic retrograde cholangiopancreatography; primary sclerosing cholangitis; *clostridium difficile* infection; metronidazole; ultrasonographic examination

## Case Report:

A 38-year-old man was admitted to the hospital because of evidence of biliary obstruction and 3 kg lost in weight during the last two weeks. One year before admission, the patient was admitted to another hospital because of bloody diarrhea, when the serum aspartate aminotransferase level was 100 U per liter and a test for *Clostridium Difficile* was positive. He had not taken antibiotics before the onset of symptoms and it was prescribed one-month of metronidazole. The patient condition was well until several weeks before admission, when he began to have no radiating colicky pain in the epigastrium, right upper quadrant, and periumbilical area; the pain was exacerbated by eating and was accompanied by nausea. He also began to have intermittent loose stools without frequent or voluminous diarrhea. During the two weeks before admission, his temperature rose intermittently to 38.3<sup>0</sup> C. Five days before admission, the patient had left-sided pleuritic chest pain and a dry cough. He went to another hospital, where leukocytosis with a left-ward shift was found.

Findings on a radiograph of the chest suggested the presence of pneumonia of the right lower lobe; there was bilateral prominence of the interstitial markings. An abdominal ultrasonographic examination revealed no abnormalities and because the pain was constantly and the no medication effective the patient was transferred to our hospital.

The patient was an advocate with no history of the use of alcohol and no family history of inflammatory bowel disease or rheumatic disorders. The temperature was 37.8<sup>0</sup> C, the pulse was 85, the respiration rate was 20, and the blood pressure was 120/55mm/Hg. Physical examination revealed mild scleral icterus and marked tenderness over the sternum on palpation, with abdomen soft with slight tenderness in the right upper quadrant; there was no hepatomegaly. No protozoa or helminthic ova were found on microscopical examination of the stool; assay of a stool culture yielded no enteric pathogens. The urine was positive for bile and for urobilinogen. Laboratory test were performed (Tables 1, 2, 3).

VARIABLE	FIVE DAYS BEFORE ADMISSION	ON ADMISSION
Albumin (g/dl)	3.1	2.3
Bilirubin (mg/dl)		
Total	2	3.1
Conjugated	1	2.6
Cholesterol(mg/dl)		104
Alanine aminotransferase (U/liter)	144	108
Aspartate aminotransferase (U/liter)	74	119
Alkaline phosphatase (U/liter)	601	629
Amylase		Normal
Lipase		Normal

**Table 1.** Blood Chemical and Enzyme Values

VARIABLE	ON ADMISSION	SECOND HOSPITAL DAY
Hematocrit %	36.8	
White-cell count (per mm <sup>3</sup> )	16,000	
Differential count %		
Neutrophils	86	
Lymphocytes	7	
Monocytes	5	
Eosinophils	2	
Platelet count (per mm <sup>3</sup> )	504,000	
Prothrombin time(sec)	12.9	13.5
Partial- thromboplastin time (sec)	35.3	36.8

Table 2. Hematologic Laboratory Values

VARIABLE	RESULTS
Test for antinuclear antibodies	Positive 1:180
Test for anti-smooth-muscle antibodies	Positive 1:80
Test for antimitochondrial antibodies	Negative
Test for hepatitis A	Negative
Test for hepatitis B	Negative
Test for hepatitis C	Negative

Table 3. Results of Laboratory Tests

Radiographs of the chest revealed bilateral prominence of the interstitial markings. An ultrasonographic examination of the abdomen showed that the liver had a normal texture and the intrahepatic ducts and the common bile duct were of normal diameter. The gallbladder was partially collapsed; the pancreas appeared normal. Ranitidine, Cephalexin and Acetaminophen were given, but the patient's temperature rose into the evening to 39.7<sup>o</sup> C. On the second hospital day, the patient's temperature did not exceed 39<sup>o</sup> C and the abdominal pain had ceased. A computed tomographic (CT) examination of the abdomen and pelvis performed after the oral and intravenous administration of contrast material, revealed no abnormalities.

## Discussions

A stool test for *Clostridium Difficile* toxin was positive at that time and although the illness responded to metronidazole, community-acquired *Clostridium Difficile* -related disease would be unusual in a young man, particularly in the absence of known predisposing factors. Only 1 to 3 percent of adults are healthy carriers of *Clostridium Difficile* [1, 2]. The most common risk factors for the acquisition of clinical *Clostridium Difficile* -related disease are hospitalization and the use of antibiotics;

other risk factors include advanced age, previous nonsurgical gastrointestinal procedures, an immunocompromised state, and the presence of underlying factors [3, 4]. However, it was reported that *Clostridium Difficile* infection may be associated with a relapse of symptoms in patients with inflammatory bowel disease, in whom this infection can occur even in the absence of antibiotic use [5]. In our case metronidazole was given for one month, which is longer than the recommended length of treatment for an uncomplicated *Clostridium Difficile* infection [6, 7].

During the initial illness, the patient also had a slightly elevated aspartate aminotransferase level, a finding that is not usually associated with *Clostridium Difficile* infection and that could be explained by a variety of acute or chronic diseases; most of them can rule out by his subsequent clinical course and the results of his laboratory tests.

The **differential diagnosis** in this case should focus on clinical disorders that can cause *intestinal* disease as well as *hepatobiliary* disease. (Figure 1) The two major diseases or categories of disease that can explain this patient's **intestinal disorder** are celiac sprue and inflammatory bowel disease.




Figure 1. Algorithm for diagnosis of hypertransaminemia

Celiac sprue is a well-recognized cause of enteric loss of protein and enteric malabsorption. There is a documented association between celiac sprue and autoimmune liver diseases, including autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis [8-20]. Nonspecific elevations in aminotransferase levels are common and usually resolve with a gluten-free diet. Celiac sprue is an unlikely diagnosis in the current case, because this illness generally develops in adults or in children who are younger than this patient. In addition, an acute onset of marked upper gastrointestinal symptoms is atypical of celiac disease, although in this case such symptoms could be related to the liver disease.

Our patient's illness is most consistent with the diagnosis of inflammatory bowel disease. Both ulcerative colitis and Crohn's disease are associated with intestinal protein loss and hepatobiliary disorders, including autoimmune diseases [21-24]. The initial signs, symptoms, and laboratory findings that suggest inflammatory bowel disease include diarrhea, fever, weight loss, leukocytosis, thrombocytosis, and occult blood in the stool. The patient's substernal pain may have been due to esophageal involvement. Upper gastrointestinal involvement is more

common in children with inflammatory bowel disease than in adults. In one series, 80 percent of patients with Crohn's disease and 75 percent of those with ulcerative colitis had endoscopic abnormalities such as esophagitis, gastritis, duodenitis, and upper gastrointestinal ulcers [25, 26].

The findings on radiographic and laboratory evaluation of the patient's hepatobiliary disease eliminate a number of disorders from differential diagnosis. Abdominal CT and ultrasonographic studies did not reveal evidence of stones, gallbladder disease, or biliary tract dilatation, and the liver appeared to have a normal texture. Autoimmune liver diseases are common in both ulcerative colitis and Crohn's disease. On the other hand, both primary sclerosing cholangitis and autoimmune hepatitis also occur in association with inflammatory bowel disease. Sclerosing cholangitis can involve the extrahepatic ducts, the intrahepatic ducts, or both. The frequency of this disorder in patients with inflammatory bowel disease is about 10 percent [24]. Autoimmune hepatitis characteristically involves the hepatic parenchyma, although there are variant overlap syndromes with features of both autoimmune hepatitis and primary sclerosing cholangitis. These disorders can be



differentiated by endoscopic retrograde cholangiopancreatography, evaluation of autoimmune markers, and liver biopsy. In our case, the results of marker studies are inconclusive, but a test for perinuclear

antineutrophil cytoplasmic antibodies might have been diagnostically helpful (Table 4).


MARKER	POSITIVE TEST RESULT	NEGATIVE TEST RESULT	RESULT IN CURRENT CASE
Antinuclear antibodies	Autoimmune hepatitis Primary sclerosing cholangitis		Weakly positive
Anti- smooth-muscle antibodies	Autoimmune hepatitis Primary sclerosing cholangitis		Positive
Antimitochondrial antibodies	Primary biliary cirrhosis	Autoimmune hepatitis Primary sclerosing cholangitis	Negative
Perinuclear antineutrophil cytoplasmic antibodies	Primary sclerosing cholangitis		Not reported

**Table 4.** Markers of Autoimmune Liver Disease

The **clinical diagnosis** of autoimmune hepatobiliary disease associated with inflammatory bowel disease is based on the patients symptoms and the presence of a protein-losing enteropathy which are more suggestive of **Crohn disease**, while moderate increases in the aminotransferase levels in proportion to the increase in the bilirubin level suggesting the diagnosis of **primary sclerosing cholangitis**.


For the pathological diagnosis the first diagnostic procedure proposed was a liver biopsy, but the insufficiency of technical resources

and no positive patient s accord for this procedure we performed an *endoscopic retrograde cholangiopancreatographic study*. It was ruled out obstruction of the extrahepatic bile ducts, a condition that can be associated with hepatic changes similar to those of primary sclerosing cholangitis. Examination of the both gastric fundus (Figure 2) and the duodenum (Figure 3) showed severe inflammation and an epithelioid granuloma in the gastric wall; there was patchy, superficial inflammation as well as deep acute and chronic inflammation. All of these findings are diagnostic of Crohn disease.



**Figure 2.** Specimen of the Gastric Fundus (Hematoxylin and Eosin, x 125) There is a granulomatous reaction around a damaged gastric gland.





**Figure 3.** Specimen of the Duodenum (Hematoxylin and Eosin x 125) The central duct is acutely inflamed and ruptured and is surrounded by acute and chronic inflammation.

We decided to begin **treatment** with ursodiol (300 mg twice daily) and prednisone (20 mg daily), treatment administrated for 4 weeks since the biochemical values return to normal, except for 5-nucleotidase value, which remained slightly elevated. The dose of prednisone was tapered during 6 months until discontinued and replaced with mesalamine. Thirty-six months after the diagnoses were made, the patient's aminotransferase levels were still slightly elevated, and his gamma-glutamyltransferase level was still moderate elevated. A repeat endoscopic retrograde cholangiopancreatogram showed no change in the degree of narrowing of the intrahepatic bile ducts. Once the synthetic function of the liver is sufficiently compromised, the only therapeutic option is transplantation. Ursodiol lowers the aminotransferase levels and improves the biochemical profile but does not affect the long-term outcome [27].

## References

1. Kaufman E, Liska D, Rubinshteyn V, Nandakumar G. (2013). Clostridium difficile bacteremia. *Surg Infect (Larchmt)*. 14(6):559-60.
2. Kyne L, Warny M, Qamar A, Kelly CP. (2000). Asymptomatic carriage of *Clostridium difficile* and serum levels of IgG antibody against toxin A. *N Engl J Med*. 342: 390-7.
3. Bignardi GE. (1998). Risk factors for *Clostridium difficile* infection. *J Hosp Infect* 40:1-15.
4. Sjøes LM, Holt HM, Böttiger B, Nielsen HV, Andreasen V, Kemp M, Olsen KE, Ethelberg S, Mølbak K. (2014). Risk factors for *Clostridium difficile* infection in the community: a case-control study in patients in general practice, Denmark, 2009-2011. *Epidemiol Infect*. 142(7):1437-48.
5. Gryboski JD. (1991). Clostridium difficile in inflammatory bowel disease relapse. *J Pediatr Gastroenterol Nutr*. 13:39-41.
6. Farne HA, Martin NK, Main J, Orchard T, Tyrrell-Price J. (2013). C-reactive protein is a useful predictor of metronidazole treatment failure in mild-to-moderate *Clostridium difficile* infection. *Eur J Gastroenterol Hepatol*. 25(1):33-36.
7. Dupont HL. (2013). Diagnosis and management of *Clostridium difficile* infection. *Clin Gastroenterol Hepatol*. 11(10):1216-1223.
8. Kingham JG, Parker DR. (1998). The association between primary biliary cirrhosis and celiac disease: a study of relative prevalences. *Gut*. 42(1):120-122.
9. Dickey W, McMillan SA, Callender ME. (1997). High prevalence of celiac sprue among patients with primary biliary cirrhosis. *J Clin Gastroenterol*. 25(1):328-329.
10. Sorensen HT, Thulstrup AM, Blomqvist P, Norgaard B, Fonager K, Ekbohm A. (1999). Risk of primary biliary cirrhosis in patients with celiac disease: Danish and Swedish cohort data. *Gut*. 44(5):736-738.
11. Gillett HR, Cauch-Dudek K, Jenny E, Heathcote EJ, Freeman HJ. (2000). Prevalence of IgA antibodies to endomysium and tissue transglutaminase in primary biliary cirrhosis. *Can J Gastroenterol*. 14(8):672-675.
12. Volta U, Rodrigo L, Granito A, et al. (2002). Celiac disease in autoimmune cholestatic liver disorders. *Am J Gastroenterol*. 97(10):2609-2613.

13. Floreani A, Betterle C, Baragiotta A, et al. (2002). Prevalence of celiac disease in primary biliary cirrhosis and of antimicrobial antibodies in adult celiac disease patients in Italy. *Dig Liver Dis*. 34(4):258–261.
14. Bizzaro N, Villalta D, Tonutti E, et al. (2003). IgA and IgG tissue transglutaminase antibody prevalence and clinical significance in connective tissue diseases, inflammatory bowel disease, and primary biliary cirrhosis. *Dig Dis Sci*. 248(12):2360–2365.
15. Lawson A, West J, Aithal GP, Logan RF. (2005). Autoimmune cholestatic liver disease in people with celiac disease: a population-based study of their association. *Aliment Pharmacol Ther*. 21(4):401–405.
16. Hay JE, Wiesner RH, Shorter RG, LaRusso NF, Baldus WP. (1988). Primary sclerosing cholangitis and celiac disease. A novel association. *Ann Intern Med*. 109(9):713–717.
17. Freeman HJ, Kwan WC. (1994). Occult celiac disease associated with lymphocytic sclerosing cholangitis. *Can J Gastroenterol*. 8:249–252.
18. Venturini I, Cosenza R, Miglioli L, et al. (1998). Adult celiac disease and primary sclerosing cholangitis: two case reports. *Hepatogastroenterology*. 45(25):2344–2347.
19. Wurm P, Dixon AD, Rathbone BJ. (2003). Ulcerative colitis, primary sclerosing cholangitis and celiac disease: two cases and review of the literature. *Eur J Gastroenterol Hepatol*. 15(7):815–817.
20. Al-Osaimi AM, Berg CL. (2004). Association of primary sclerosing cholangitis and celiac disease: a case report and review of the literature. *Dig Dis Sci*. 49(3):438–443.
21. Issa M, Vijayapal A, Graham MB, et al. (2007). Impact of *Clostridium difficile* on inflammatory bowel disease. *Clin Gastroenterol Hepatol*; 5: 345–351.
22. Powell N, Jung SE, Krishnan B. (2008). *Clostridium difficile* infection and inflammatory bowel disease: a marker for disease extent? *Gut*; 57: 1183–1184.
23. Khor B, Gardet A, Xavier RJ. (2011). Genetics and pathogenesis of inflammatory bowel disease. *Nature*; 474: 307–317.
24. Heikius B, Niemela S, Lehtola J, Karttunen T, Lahde S. (1997). Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease. *Scand J Gastroenterol*. 32:153–161.
25. Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A. (2009). Impact of *Clostridium difficile* infection on pediatric inflammatory bowel disease. *J Pediatr*.
26. Jen MH, Saxena S, Bottle A, Aylin P, Pollok RC. (2011). Increased health burden associated with *Clostridium difficile* diarrhoea in patients with inflammatory bowel disease. *Aliment Pharmacol Ther*; 33: 1322–1331.
27. Jodorkovsky D, Young Y, Abreu MT. (2010). Clinical outcomes of patients with ulcerative colitis and co-existing *Clostridium difficile* infection. *Dig Dis Sci* 2010; 55: 415– 420.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here: [Submit Manuscript](#)

DOI: [10.31579/2690-1919/166](https://doi.org/10.31579/2690-1919/166)

#### Ready to submit your research? Choose Auctores and benefit from:

- ❖ fast, convenient online submission
- ❖ rigorous peer review by experienced research in your field
- ❖ rapid publication on acceptance
- ❖ authors retain copyrights
- ❖ unique DOI for all articles
- ❖ immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more [www.auctoresonline.org/journals/journal-of-clinical-research-and-reports-](http://www.auctoresonline.org/journals/journal-of-clinical-research-and-reports-)